Mark B. Benjamin President & Chief Executive Officer
Mark comes to Galenea with 16 years of industry experience, 13 in business development. He was most recently the Chief Business Officer of Nura Inc., a neuroscience drug discovery company founded by 2004 Nobel laureate Dr. Linda Buck, which was acquired by Omeros Inc. in 2006. In previous positions, he served as Vice President of Global Business Development for Manteia SA, a Swiss-based subsidiary of Serono SA (now Merck KGaA) and was the senior business development executive at Rosetta Inpharmatics, a company founded by a team that included 2001 Nobel laureate Leland Hartwell. Rosetta was acquired by Merck & Company in 2001. Mark received a first class B.Sc. degree with honors from the University of London and a D.Sc. degree in Cancer Biology from Harvard University.

David J. Gerber Vice President, CNS Research
David is a founding scientist at Galenea. He has more than ten years of experience in CNS research primarily in the areas of psychiatric disease biology, molecular and behavioral neuroscience and mouse molecular genetics. Recently, his research has focused on the genetics of schizophrenia and particularly on the involvement of calcineurin dysfunction in schizophrenia pathogenesis. David received a bachelor's degree in mathematics from MIT in 1987 and a Ph.D. in biology from MIT in 1996. David pursued his postdoctoral research in Dr. Susumu Tonegawa's laboratory at the Picower Institute for Learning and Memory at MIT prior to joining Galenea in 2004.

Geraldine C. Harriman Vice President, Chemistry
Gerry has over fourteen years experience in the biotechnology industry in which she successfully delivered multiple "first in class" compounds against novel targets into clinical development. Prior to joining Galenea as Vice President of Chemistry, she was Senior Director of Chemistry at Millennium Pharmaceuticals responsible for the inflammation small molecule portfolio. Prior to her role at Millennium, she was one of the founding medicinal chemists at LeukoSite. Gerry received her Ph.D. from the University of Rhode Island, followed by postdoctoral research at the University of Kansas. She is an author of over thirty publications, an author of several book chapters and an inventor on over fifteen small molecule patents.

Michael D. Rivard, J.D. Head of Corporate Development
Mike brings over 15 years of experience in the biotechnology industry. He joined Galenea in February 2005 and has held a variety of positions, most recently Head of Corporate Development. Before that, he held the position of Vice President, Business Development, at Synta Pharmaceuticals, and the positions of Vice President, Strategic Development, and Vice President, Legal, and General Counsel at ArQule. Mike was also associate counsel (intellectual property) at the University of Massachusetts System and an associate at the law firm of Palmer & Dodge. Mike holds an undergraduate degree in biochemistry, summa cum laude, from Bowdoin College and a graduate degree in law, Order of the Coif, from UCLA.

David Neafus Chief Financial Officer
Prior to joining Galenea, David, over the previous 14 years, has operated his own consulting firm providing executive services, specializing in interim executive management, IPOs, turnarounds, strategic analysis, and mergers and acquisitions. Previous clients include GlycoFi, where as CFO David helped the company complete its $400 Million acquisition by Merck, Alnylam Pharmaceuticals, Inc. where as Vice President of Finance, David led the company to a successful IPO, Infinity Pharmaceuticals where David served as Vice President Finance and Administration and Millennium Pharmaceuticals where he served as Corporate Controller. Prior to running his own consulting firm, David was an auditor at KPMG for 4½ years. David received his bachelor's degree in accounting from the University of Minnesota, and his MBA from Bentley College. He is also a certified public accountant.